Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adoptive T Cell Therapy, DC1 Vaccine, Pepinemab, and Trastuzumab in Metastatic HER2-Positive Breast Cancer
NCT05378464Phase 1Suspended
- Sponsor
- Moffitt Cancer Center
- Start
- May 2022
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial in breast cancer (4 arms), sponsored by Moffitt Cancer Center. Primary endpoint: Maximum Tolerated Dose at 6 months. Started May 2022; status: suspended.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05378464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05378464.